Clinical trials: HSV Infection
Herpes Zoster
ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)
The purpose of the study is to evaluate the general safety of ZOSTAVAX™ in subjects 60 years of age or older as required by the FDA.
- Trial name
- NCT00550745
- Testing
- Zoster Vaccine, Live
- Volunteers
- 11,999 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster, Shingles
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
The purpose of this study is to assess the safety and immunogenicity of amezosvatein (CRV-101), an investigational vaccine compared to Shingrix® for the prevention of herpes zoster in adults aged 50 years and older
- Trial name
- NCT05304351
- Testing
- Amezosvatein Antigen High Dose Arm A, Amezosvatein Antigen Low Dose Arm B, Shingrix
- Where
- 14 sites in United States
- Volunteers
- 1,516 people, healthy volunteers welcome
- Sponsor
- Curevo Inc
Herpes Labialis
Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis
Currently approved drugs for the treatment of herpes labialis (cold sores) exhibit low levels of efficacy due to the limited ability of the drugs to penetrate the skin to the site where the herpes virus is replicating.
- Trial name
- NCT00230867
- Testing
- iontophoretic acyclovir
- Where
- 26 sites in United States
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Transport Pharmaceuticals
Herpes Zoster, Shingles
ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)
This study will evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ in Korean adults. Approximately 180 herpes zoster history negative subjects ≥ 50 years of age will be enrolled in the study.
- Trial name
- NCT01556451
- Testing
- Zoster Vaccine Live
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
This study assesses non-inferiority by comparing GMR(Geometric Mean Ratio) of NBP608 to Zostavax which are evaluated by gpELISA (Glycoprotein Enzyme Linked Immunosorbent Assay).
- Trial name
- NCT03116594
- Testing
- NBP608, Zostavax
- Where
- South Korea
- Volunteers
- 675 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Vaccine-Preventable Diseases, Herpes Zoster
A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine
This clinical trial is to study protective efficacy and safety of a recombinant herpes zoster vaccine (LZ901) and sponsored by Beijing Luzhu Biotechnology Co., Ltd.
- Trial name
- NCT06088745
- Testing
- Recombinant Herpes Zoster Vaccine
- Where
- China
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Beijing Luzhu Biotechnology Co., Ltd.
Herpes Simplex Type Two Infection, HIV Infections
Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix
Herpes simplex virus type 2 (HSV2), the most common cause of genital herpes, increases a woman's risk of HIV acquisition from 3-6 fold, perhaps because HSV2-infected women have increased numbers of HIV "target cells" (CD4 T cells…
- Trial name
- NCT00946556
- Testing
- Valacyclovir
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Shingles
Optimal Timing of Zoster Vaccine After Zoster Illness
The purpose of this study is to determine the optimal timing of zoster vaccination to induce both higher cell-mediated immunity and humoral immunity in adult patients aged over 50 with history of zoster within 5 years.
- Trial name
- NCT02704572
- Testing
- Zostavax
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Herpes Simplex
Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine
Evaluate, one month after the third dose, the lot-to-lot consistency of 3 different commercial scale production lots of the candidate vaccine in healthy HSV 1-/2- females aged 10-17 years, determined by ELISA.
- Trial name
- NCT00224471
- Testing
- GSK208141 vaccine
- Where
- 13 sites in United States, Belgium and 1 more
- Volunteers
- 671 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chickenpox, Herpes Zoster
Immune Response to Varicella-Zoster Vaccination and Infection
Background: The common varicella-zoster virus causes both chickenpox and shingles. Both diseases cause rashes, but they can also have complications such as bacterial infections of the skin, pneumonia, or eye disease.
- Trial name
- NCT00921999
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).
To evaluate the lot-to lot consistency of three batches of recombinant herpes zoster vaccine (CHO cell) produced on a commercial scale in subjects aged 40 years and older after receiving 2 doses on a 0, 2 month schedule.
- Trial name
- NCT06654700
- Testing
- Recombinant Zoster Vaccine (CHO Cell)
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Herpes Zoster
Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects
The subjects included in this study are subjects that participated in study NCT00434577. These subjects were vaccinated with the candidate Herpes Zoster (HZ) vaccine at Month 0 and Month 2 and were then followed at Month 12…
- Trial name
- NCT01295320
- Testing
- Blood sample
- Where
- 11 sites in Czechia, Germany and 2 more
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes
Bioequivalency Study of Famciclovir 500 mg Tablets Under Fasted Conditions
The objective of this study was to prove the bioequivalence of Famciclovir 500 mg Tablets under fasting conditions.
- Trial name
- NCT01321515
- Testing
- famciclovir
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories